• NBC19 for Reproducible NLRP3 Assays

  2026-09-15

  A scenario-based guide to using NBC19 (SKU BA6129) as an NLRP3 inflammasome inhibitor in cytokine, viability, and cytotoxicity workflows. It connects product-backed potency and handling data with practical assay design, interpretation, and vendor-selection decisions.

• Hexose Diphosphate: Designing Better Metabolic Assays

  2026-09-15

  Hexose diphosphate is a versatile hexose phosphate for connecting glycolytic flux with energy homeostasis research. This article explains how to use it responsibly in metabolic and inflammation workflows while distinguishing pathway effects from direct signaling mechanisms.

• TRIM21–ERK1/2 Signaling in Pituitary Adenomas

  2026-09-14

  The reference study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, pituitary adenoma proliferation, and resistance to dopamine-directed therapy. By combining CRISPR screening, biochemical validation, animal studies, and NanoBiT drug screening, it nominates TRIM21 suppression—and compounds such as Quisinostat—as a mechanistically testable strategy.

• Network Medicine Identifies Apigenin for Alzheimer’s

  2026-09-14

  A 2025 study used network proximity analysis to screen flavonoids against Alzheimer’s disease targets and identified Apigenin as the leading candidate among four experimentally tested compounds. Cellular validation linked its neuroprotective activity to mitochondrial preservation, reduced apoptosis, AKT/NF-κB pathway suppression, and regulation of microglial inflammatory states.

• Curcumin, NLRP3, and HUVEC Pyroptosis

  2026-09-13

  A study in Molecular Medicine Reports shows that curcumin protects human umbilical vein endothelial cells from H2O2-induced injury by suppressing NLRP3-associated pyroptosis. Its use of caspase-1 and NLRP3 inhibitors strengthens the mechanistic interpretation and provides a practical framework for studying endothelial inflammation.

• Ziprasidone HCl: Mechanisms and Research Benchmarks

  2026-09-12

  Ziprasidone HCl combines established serotonin–dopamine receptor pharmacology with reported GOT1 inhibition in pancreatic cancer models. This article separates clinical neuropsychiatric use from preclinical oncology evidence and organizes assay, formulation, and dosing parameters for reproducible research.

• Alternariol (AOH): Mechanisms & Research Workflow

  2026-09-11

  Alternariol, also called AOH, is an emerging Alternaria mycotoxin with documented effects on steroid secretion, cell viability, apoptosis, cytoskeletal proteins, and hepatic stellate-cell activation. This article separates established product and literature findings from practical assay recommendations for mycotoxin research, cytochrome P450 enzyme assays, and apoptosis mechanism research.

• Lactate–HMGB1 Signaling in Polymicrobial Sepsis

  2026-09-11

  The reference study identifies lactate as an active regulator of macrophage HMGB1 modification and exosomal release, rather than merely a clinical marker of sepsis severity. Its integrated cell, genetic, exosome, endothelial, and mouse experiments connect lactate transport and GPR81-associated signaling with vascular permeability and survival, offering a mechanistic framework for inflammation research.

• Early Life Adversity, Oxytocin, and Innate Fear

  2026-09-10

  This 2026 Communications Biology study links early life adversity to impaired looming-evoked defensive behavior in mice and identifies deficient oxytocin signaling in the superior colliculus as a mechanistic pathway. Its combination of developmental stress modeling, circuit analysis, receptor manipulation, and intranasal oxytocin rescue provides a framework for studying how early experience alters innate threat processing.

• ALC-0315 LNP Mixing: Workflow and Troubleshooting

  2026-09-10

  Build more reproducible mRNA lipid nanoparticles with ALC-0315 by treating mixing as a formulation variable, not merely a transfer step. This workflow connects stock handling, flow regime, physicochemical QC, and biological testing to improve the relevance of bench-scale results for therapeutic mRNA delivery.

• Triptolide and Transcriptional Stress

  2026-09-09

  Triptolide (PG490) is more than a cytotoxic natural product: it is a powerful probe of transcriptional stress, immune signaling, and tissue-barrier biology. This article connects its CDK7–RNAPII mechanism with new acute pancreatitis findings to improve assay design and interpretation.

• VX-745: p38α MAPK Inhibitor Workflows

  2026-09-09

  VX-745 combines nanomolar p38α inhibition with practical utility across cytokine, oncology, aging, and arthritis research. This guide converts its biochemical profile into reproducible cell-assay workflows, mechanistic controls, and troubleshooting strategies.

• NF 449: From P2X1 Blockade to Assay Design

  2026-09-08

  NF 449 is a potent purinergic receptor antagonist for resolving P2X1-dependent platelet signaling. This guide interprets potency across recombinant, native-cell, and thrombosis models while translating the evidence into better platelet assay design.

• Fucoidan and Cancer Plasticity: A Translational Roadmap

  2026-09-08

  Fucoidan is more than a broadly described marine polysaccharide: its apoptosis, angiogenesis, and immune-modulating activities create a useful framework for translational oncology. This article connects those findings with cancer-cell plasticity research and outlines a disciplined path from mechanistic hypothesis to reproducible model validation.

• Triptolide (PG490) Experimental Workflow

  2026-09-07

  Triptolide (PG490) is a nanomolar transcriptional perturbagen for cancer, immune, and inflammatory research. This guide translates its RNAPII, IL-2, NF-κB, MMP, and AhR–HSF1 applications into practical workflows, controls, and troubleshooting strategies.

8489 records 1/566 page Next 12345 下5页 Last page